KEAP1 and inflammatory bowel disease: Rutaecarpine and carnosic acid ameliorated inflammatory responses in DSS-induced colitis mice via Nrf2 activation by interfering with Keap1-Nrf2 binding [42, 43]; such attempts have shown promise as emerging therapeutic strategies for IBD.